Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

  • Lisa Bodei
  • Marta Cremonesi
  • Mahila Ferrari
  • Monica Pacifici
  • Chiara M. Grana
  • Mirco Bartolomei
  • Silvia M. Baio
  • Maddalena Sansovini
  • Giovanni Paganelli
Original Article

Abstract

Purpose

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with 90Y-DOTATOC and 177Lu-DOTATATE is promising. The kidney is the critical organ and despite renal protection, function loss may become evident years later. The aim of this study was to analyse renal parameters in patients who had undergone dosimetry before PRRT.

Methods

Among those in protocols at our institution, 28 patients were considered: 23 received 90Y-DOTATOC (3.8–29.2 GBq, median 12.2) and five received 177Lu-DOTATATE (20.7–29.2 GBq, median 23.2). Patients were followed up after therapy for creatinine and creatinine clearance loss (CCL) for 3–97 months (median 30). Renal doses and bio-effective doses (BED) were calculated (MIRD, LQ model).

Results

After 90Y-DOTATOC toxicity on creatinine according to NCI criteria occurred in nine cases (seven grade 1, one grade 2, one grade 3), CCL at 1 year was >5% in 12 cases and >10% in eight. A 28-Gy BED threshold was observed in patients with risk factors (mainly hypertension and diabetes), while it was 40 Gy in patients without risk factors. Probably due to the low number of patients, despite the absence of severe toxicity after hyper-fractionated PRRT, clear correlations between fractionation and toxicity could not be found. After 177Lu-DOTATATE, no toxicity occurred in 1–2 year follow-up; CCL at 1 year >5% occurred in three patients and >10% in two.

Conclusions

Our results indicate the importance of clinical screening for risk factors: In this case, a BED <28 Gy is recommended. Fractionation of therapy is important in order to decrease toxicity, and further studies are needed to evaluate its clinical impact.

Keywords

Renal toxicity 90Y-DOTATOC 177Lu-DOTATATE Radionuclide therapy Dosimetry 

References

  1. 1.
    de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002;32(2):133–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43(5):610–6.PubMedGoogle Scholar
  3. 3.
    Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(Suppl 1):62S–6S.PubMedGoogle Scholar
  5. 5.
    Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32(2):110–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23(12):2754–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. d-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38(12):1929–33.PubMedGoogle Scholar
  8. 8.
    de Jong M, Krenning EP. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43(5):617–20.PubMedGoogle Scholar
  9. 9.
    Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28(4):426–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16.PubMedGoogle Scholar
  11. 11.
    Bodei L, Cremonesi M, Grana C, Bartolomei M, Baio SM, Bufi G, et al. Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33(Suppl 2):S214.Google Scholar
  12. 12.
    Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591–603.PubMedCrossRefGoogle Scholar
  13. 13.
    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Al-Said J, Brumback MA, Moghazi S, Baumgarten DA, O'Neill WC. Reduced renal function in patients with simple renal cysts. Kidney Int 2004;65(6):2303–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamazaki H, Oi H, Matsushita M, Kim T, Tanaka E, Inoue T, et al. Renal cortical retention on delayed CT and nephropathy following transcatheter arterial chemoembolisation. Br J Radiol 2001;74(884):695–700.PubMedGoogle Scholar
  16. 16.
    Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. Am J Med Sci 2007;334(2):115–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Savi A, Lecchi M, Albertini F, Chiesa C, Gilardi MC, Bombardieri E, et al. Evaluation of attenuation correction in planar In-111 biodistribution studies [abstract]. Eur J Nucl Med Mol Imaging 2004;31(Suppl):S229.Google Scholar
  18. 18.
    Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47(9):1467–75.PubMedGoogle Scholar
  19. 19.
    Cremonesi M, Ferrari M, Bodei L, Bartolomei M, Chinol M, Mei R, et al. Dosimetry in patients undergoing 177Lu-DOTATATE therapy with indications for 90Y-DOTATATE. Eur J Nucl Med Mol Imaging 2006;33(Suppl 1):S102. Abs 91.Google Scholar
  20. 20.
    Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates: MIRD pamphlet no16. J Nucl Med 1999;40(2):S37–S61.Google Scholar
  21. 21.
  22. 22.
    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023–27.PubMedGoogle Scholar
  23. 23.
    Foster D, Barret P (editors). Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system. In: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, Tennessee: Oak Ridge Institute for Science and Education;1998.Google Scholar
  24. 24.
    Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharm 2004;19(3):363–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Thames HD, Ang KK, Stewart FA, van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol 1988;54(1):13–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med 2005;46(Suppl 1):99S–106S.PubMedGoogle Scholar
  27. 27.
    Cybulla M, Weiner SM, Otte A. End-stage renal disease after treatment with 90Y-DOTATOC. Eur J Nucl Med 2001;28(10):1552–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26(11):1439–47.PubMedCrossRefGoogle Scholar
  29. 29.
    Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl 1):83S–91S.PubMedGoogle Scholar
  30. 30.
    National Council on Radiation Protection and Measurements. Misadministration of radioactive material in medicine–scientific background. Bethesda, MD 1991:27Google Scholar
  31. 31.
    Cassady JR. Clinical radiation nephropathy. Int J Radiat Oncol Biol Phys 1995;31(5):1249–56.PubMedGoogle Scholar
  32. 32.
    Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.PubMedCrossRefGoogle Scholar
  33. 33.
    Walrand S, Jamar F, Mathieu I, De Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. Eur J Nucl Med Mol Imaging 2003;30:354–61.PubMedGoogle Scholar
  34. 34.
    Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20(1):47–51.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Lisa Bodei
    • 1
  • Marta Cremonesi
    • 2
  • Mahila Ferrari
    • 2
  • Monica Pacifici
    • 1
  • Chiara M. Grana
    • 1
  • Mirco Bartolomei
    • 1
  • Silvia M. Baio
    • 1
  • Maddalena Sansovini
    • 1
    • 3
  • Giovanni Paganelli
    • 1
  1. 1.Division of Nuclear MedicineEuropean Institute of OncologyMilanItaly
  2. 2.Health Physics DivisionsEuropean Institute of OncologyMilanItaly
  3. 3.Department of Nuclear MedicineUniversity of BolognaBolognaItaly

Personalised recommendations